ZLAB

Zai Lab Ltd

ZLAB, USA

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.

https://www.zailaboratory.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ZLAB
stock
ZLAB

How Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals simplywall.st

Read more →
ZLAB
stock
ZLAB

Zai Lab stock hits 52-week low at $18.77 By Investing.com Investing.com UK

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$49.4882

Analyst Picks

Strong Buy

7

Buy

4

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.58

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-4.73 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.10 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-31.12 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.53

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 52.92% of the total shares of Zai Lab Ltd

1.

FMR Inc

(5.5697%)

since

2025/06/30

2.

Capital World Investors

(5.4248%)

since

2025/06/30

3.

RTW INVESTMENTS, LLC

(4.976%)

since

2025/06/30

4.

ClearBridge Advisors, LLC

(3.6056%)

since

2025/06/30

5.

Capital Group New Geography Equity Comp

(2.9425%)

since

2025/06/30

6.

American Funds New World A

(2.9425%)

since

2025/06/30

7.

HHG PLC

(1.9752%)

since

2025/06/30

8.

American Funds SMALLCAP World A

(1.872%)

since

2025/06/30

9.

ClearBridge International Growth EAFE

(1.8112%)

since

2025/07/31

10.

ClearBridge International Growth C

(1.8112%)

since

2025/07/31

11.

Fidelity Contrafund

(1.4906%)

since

2025/07/31

12.

BAMCO Inc

(1.427%)

since

2025/06/30

13.

Wellington Management Company LLP

(1.2375%)

since

2025/06/30

14.

Baron Emerging Markets Strategy

(1.2184%)

since

2025/06/30

15.

Baron Emerging Markets Institutional

(1.2184%)

since

2025/06/30

16.

Woodline Partners LP

(1.0794%)

since

2025/06/30

17.

Allianz Asset Management AG

(0.8376%)

since

2025/06/30

18.

Rock Springs Capital Management LP

(0.7831%)

since

2025/06/30

19.

ADAR1 Capital Management LLC

(0.7643%)

since

2025/06/30

20.

MPM Oncology Impact Management LP

(0.6696%)

since

2025/06/30

21.

Allianz Oriental Income P USD

(0.6375%)

since

2025/07/31

22.

Principal International All Country Eq

(0.5814%)

since

2024/12/31

23.

Fidelity Contrafund Commingled Pl S

(0.5662%)

since

2025/07/31

24.

T. Rowe Price Health Sciences

(0.5594%)

since

2025/07/31

25.

Janus Henderson Global Life Sciences D

(0.5486%)

since

2025/06/30

26.

Janus Henderson Global Life Sciences

(0.5486%)

since

2025/06/30

27.

Jennison Associates LLC

(0.5323%)

since

2025/06/30

28.

Strategic Advisers Fidelity Em Mkts

(0.5013%)

since

2025/07/31

29.

Fidelity Series Emerging Markets

(0.498%)

since

2025/07/31

30.

CAM Group Holding A/S

(0.4583%)

since

2025/06/30

31.

C WorldWide Healthcare Select 1A

(0.4583%)

since

2025/07/31

32.

Janus Global Life Science AUSD

(0.456%)

since

2025/06/30

33.

Janus Henderson Glb Life Scn I2 USD

(0.4454%)

since

2025/07/31

34.

Fidelity Growth Compy Commingled Pl S

(0.4406%)

since

2025/07/31

35.

BlackRock Inc

(0.4092%)

since

2025/06/30

36.

B Group, Inc

(0.3595%)

since

2025/06/30

37.

Connor Clark & Lunn Inv Mgmt Ltd

(0.3481%)

since

2025/06/30

38.

Citadel Advisors Llc

(0.3291%)

since

2025/06/30

39.

XY Capital Ltd

(0.3259%)

since

2025/06/30

40.

Morgan Stanley - Brokerage Accounts

(0.2598%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.0882

Latest Release

Date

2025-09-30

EPS Actual

-0.33

EPS Estimate

-0.2453

EPS Difference

-0.0847

Surprise Percent

-34.5291%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.